Your Source for Venture Capital and Private Equity Financings

CARGO Therapeutics Lands $200M Series A

2023-03-01
SAN MATEO, CA, CARGO Therapeutics, a biotechnology company, announced the close of a $200 million oversubscribed and upsized Series A financing.
CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, announced the close of a $200 million oversubscribed and upsized Series A financing.

The financing was co-led by Third Rock Ventures, RTW Investments, LP and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.

CARGO is advancing what will potentially be a first and best-in-class autologous CD22 chimeric antigen receptor T-cell (CAR T) therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors